



March 19th, 2020
BioComo Inc.

Notice of embarking on SARS-CoV-2 vaccine development

BioComo embarks on the development of recombinant pandemic coronavirus (SARS-CoV-2) vaccines using BC-PIV and VLP/BC-PIV vectors in collaboration with Professor Nosaka, Mie University Graduate School of Medicine.

BC-PIV and VLP/BC-PIV vectors are BioComo's proprietary platform technology that enable the delivery of conformationally maintained large antigenic proteins.

Recombinant Ebola virus vaccine (*) and respiratory syncytial virus vaccine were produced using the technology.

We now apply this technology to a Spike (S) protein of SARS-CoV-2 for the vaccine candidates. Four conformationally-stabilized mutant S proteins are used as vaccine antigens. Animal testing will be conducted most likely in about as early as 2 months.

(*) : <https://www.ncbi.nlm.nih.gov/pubmed/31501502>

【About BioComo Inc.】

Privately held biotech company, founded in May 2008

Head Office : 1325 Komono, Mie-gun, Mie, Japan 510-1233

Executive Member:

Masayuki Fukumura, Ph.D., Founder, CEO & CSO

Hiromu Ozaki, Board, BD

Hiroki Hideshima, Board, CFO

Mitsuhiro Fujita, Board

URL: <http://biocomo.jp/>

Category of Business: Vaccines against infectious diseases and
Immunomodulators for solid tumors

BC-PIV Technology: <https://www.ncbi.nlm.nih.gov/pubmed/24942630>

Contact : info@biocomo.jp